

## Online Resource 2

**Article title:** Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

**Journal:** *Clinical Rheumatology*

**Authors:** Désirée van der Heijde, Patrick Durez, Georg Schett, Esperanza Naredo, Mikkel Østergaard, Gabriella Meszaros, Francesco De Leonardis, Inmaculada de la Torre, Pedro López-Romero, Douglas Schlichting, Eric Nantz, Roy Fleischmann

**Affiliation of corresponding author:** Leiden University Medical Center, Leiden, The Netherlands, email address: mail@dvanderheijde.nl

Patient baseline characteristics grouped by SDAI score and treatment (SDAI-Group A: sustained SDAI score  $\leq 11$  at weeks 16, 20 and 24; SDAI-Group B: SDAI score  $> 11$  or missing data at any of weeks 16, 20 and 24)

Treatment (N; % of treatment group)	SDAI-Group A (N=209)			SDAI-Group B (N=375)		
	MTX (N=53; 25.2%)	Bari (N=62; 39.0%)	Bari + MTX (N=94; 43.7%)	MTX (N=157; 74.8%)	Bari (N=97; 61.0%)	Bari + MTX (N=121; 56.3%)
Age, years	52 $\pm$ 13	51 $\pm$ 13	45 $\pm$ 14	50 $\pm$ 14	51 $\pm$ 13	51 $\pm$ 13
Female	36 (67.9)	47 (75.8)	67 (71.3)	112 (71.3)	74 (76.3)	89 (73.6)
BMI, kg/m <sup>2</sup>	26.3 $\pm$ 6.0	27.7 $\pm$ 7.4	25.7 $\pm$ 5.1	26.6 $\pm$ 6.3	26.3 $\pm$ 6.1	27.3 $\pm$ 6.5
Smoker	10 (18.9)	17 (27.4)	20 (21.3)	38 (24.2)	20 (20.6)	27 (22.3)
Duration of RA from diagnosis, years <sup>a</sup>	0.2 (0.1, 0.4)	0.2 (0.1, 0.4)	0.2 (0.1, 1.0)	0.2 (0.1, 0.7)	0.4 (0.1, 1.6)	0.2 (0.1, 1.1)
ACPA positive <sup>b</sup>	48 (90.6)	59 (95.2)	88 (93.6)	145 (92.9)	83 (85.6)	104 (86.0)
RF positive <sup>c</sup>	50 (94.3)	61 (98.4)	88 (93.6)	153 (97.5)	94 (96.9)	116 (95.9)
$\geq 1$ joint erosion	35 (66.0)	41 (66.1)	52 (55.3)	103 (66.0)	64 (66.0)	85 (70.2)
hsCRP, mg/L	16.4 $\pm$ 12.7	19.4 $\pm$ 19.2	25.7 $\pm$ 28.4	24.4 $\pm$ 23.8	26.5 $\pm$ 29.6	23.2 $\pm$ 30.3
DAS28-hsCRP	5.7 $\pm$ 0.9	5.6 $\pm$ 0.9	5.8 $\pm$ 0.9	5.9 $\pm$ 1.0	6.1 $\pm$ 1.0	6.0 $\pm$ 0.9
SDAI	39.7 $\pm$ 12.9	38.2 $\pm$ 12.4	40.9 $\pm$ 12.8	42.3 $\pm$ 14.2	45.6 $\pm$ 14.2	44.2 $\pm$ 13.6
mTSS	9.7 $\pm$ 21.8	10.5 $\pm$ 25.5	7.5 $\pm$ 14.7	12.6 $\pm$ 22.4	15.2 $\pm$ 28.0	14.9 $\pm$ 23.5
HAQ-DI total score	1.5 $\pm$ 0.7	1.5 $\pm$ 0.8	1.6 $\pm$ 0.7	1.7 $\pm$ 0.7	1.7 $\pm$ 0.7	1.6 $\pm$ 0.6

Data are reported as mean  $\pm$  standard deviation or n (%) unless otherwise indicated

<sup>a</sup>Data presented as medians with interquartile range

<sup>b</sup>ACPA positive (>ULN [ULN=10 U/mL])

<sup>c</sup>RF positive (>ULN [ULN=14 U/mL])

*ACPA* anti-cyclic citrullinated peptide antibody, *Bari* baricitinib, *BMI* body mass index, *DAS28* Disease Activity Score for 28-joint counts, *HAQ-DI* Health Assessment Questionnaire-Disability Index, *hsCRP* high-sensitivity C-reactive protein, *mTSS* van der Heijde-modified total Sharp score, *MTX* methotrexate, *RA* rheumatoid arthritis, *RF* rheumatoid factor, *SDAI* Simplified Disease Activity Index, *ULN* upper limit of normal